HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer

Results

Title:	HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer
Authors:	Maglakelidze, Marina; Ryspayeva, D; Andric, Zoran G ; Petrovic, Zeljko M; Bulat, IV; Nikolic, Ivan V ; Chawla, T; Nagarkar, R; Wiedermann, Ursula; Blumenstein, BA; Chong, LMO; Ede, NJ; Nixon, B; Good, AJ;
Issue Date:	2022
Publication:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Search Idenfier
Type:	Conference Paper
Collation:	vol. 33 br. Suppl 9 str. S1460-S1460
DOI:	10.1016/j.annonc.2022.10.110
WoS-ID:	000897943700076
URI:	https://enauka.gov.rs/handle/123456789/828156
Project:	Imugene Limited
Metadata source:	(Preuzeto iz Nasi u WoS)
Note:	ESMO Asia Congress, Singapore, SINGAPORE, DEC 02-04, 2022
M-category:	Mp. category will be shown later

Altmetric

Dimensions

Unpaywall

Google Scholar^TM